Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- This Is Why We Watch a Reality-TV Star’s Heartbreaking 10-Minute Video About His Daughter’s Leukemiaon April 9, 2021 at 9:59 am
The star of MTV's The Challenge shares how a parent makes the decision to go to palliative care for his child.
- St. Paul nurse works pregnant through pandemic, learns she has leukemia while in laboron April 9, 2021 at 3:03 am
She’s already been through a lot, pregnant in a pandemic and working as an ICU nurse. Then came the cancer diagnosis.
- Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2021 - ResearchAndMarkets.comon April 9, 2021 at 2:16 am
The “Disease Analysis: Acute Myeloid Leukemia (AML)” report has been added to ResearchAndMarkets.com’s offering. AML is a type of heterogeneous hematological malignancy that originates from immature ...
- Study suggests risk of leukemia higher in children with Down syndromeon April 8, 2021 at 5:04 pm
A new study highlighted the risks of leukemia in children with Down syndrome. It pointed to stronger than expected associations between Down syndrome and acute myeloid leukemia (AML), one type of ...
- Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemiaon April 8, 2021 at 12:35 pm
MPHOSPH8 loss inhibits acute myeloid leukemia (AML) development by reactivating LINE-1 retrotransposons. LINE-1 suppression is associated with therapy resistance and poor prognosis in patients with ...
- Relapsed Acute Myeloid Leukemia Drug Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027on April 8, 2021 at 11:03 am
Apr 08, 2021 (Market Insight Reports) -- The latest report as Relapsed Acute Myeloid Leukemia Drug Market acknowledges Size, Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, ...
- Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndromeon April 8, 2021 at 7:04 am
Ryvu Therapeutics (WSE:RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the U.S.
- Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemiaon April 7, 2021 at 5:00 am
Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor ...
- Study shows stronger link between Down syndrome and acute myeloid leukemiaon April 6, 2021 at 9:21 pm
A new large-scale study led by UC Davis Health and UC San Francisco researchers assessed the risks of leukemia in children with Down syndrome.
- Study finds risk of leukemia higher than expected in children with Down syndromeon April 6, 2021 at 12:11 pm
It pointed to stronger than expected associations between Down syndrome and acute myeloid leukemia (AML), one type of blood cancer. Down syndrome is one of the most common genetic conditions in ...
via Bing News